
Aytu BioPharma Targets 66%-67% Gross Margin by Q4 FY27, Sets $49M-$54M OpEx Plan
Aytu BioPharma has outlined an operating plan targeting 66%-67% gross margin by Q4 FY27 with $49M-$54M in operating expenses. The guidance reframes the small-cap specialty pharma's investment case around margin...























